Tech Company Inital Public Offerings
Satsuma Pharmaceuticals IPO
Satsuma Pharmaceuticals, operating out of San Francisco, had an IPO event on 9/12/2019.
Transaction Overview
Company Name
Announced On
9/12/2019
Transaction Type
IPO
Amount
$83,000,000
Proceeds Purpose
We intend to use the net proceeds from this offering as follows: approximately $18.0 million to $22.0 million to fund our Phase 3 EMERGE efficacy trial for STS101; approximately $20.0 million to $25.0 million to fund our Phase 3 safety trial for STS101; approximately $10.0 million to $12.0 million to fund manufacturing activities relating to STS101; and any remaining amounts to prepare for the commercial launch of STS101 and for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Oyster Point Blvd. 221
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Satsuma Pharmaceuticals (Nasdaq: STSA) is focused on developing best-in-class products to address the unmet needs of migraine sufferers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Kollins
Chief Financial Officer
Thomas O'Neil
Chief Medical Officer
Detlef Albrecht
Vice President
Robert Schultz
VP - Operations
Mic Iwashima
VP - Regulatory Affairs
Shannon Strom
Browse more venture capital transactions:
Prev: 9/12/2019: Hawthorne venture capital transaction
Next: 9/12/2019: Explorium venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs